NEW YORK (GenomeWeb) – Veracyte said today that Medicare administrative contractor Palmetto GBA MolDx has issued a final local coverage determination for use of its Envisia Genomic Classifier assay to clarify the diagnosis of patients with interstitial lung disease who are suspected of having idiopathic pulmonary fibrosis.
Menu
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.
By DNAnexus
Sep
16
Featured Webinar
Using Next-Generation Sequencing to Detect Genomic Mutations in Hematologic Malignancies
Sponsored by
ArcherDX
What's Popular?
In Molecular Diagnostics